Kairos Pharma, a Phase 2 biotech developing therapies for cancer, raised $6 million by offering 1.55 million shares at $4.00. The company priced the offering on Monday morning; the stock finished the day at $2.60, a decline of 35%.The Los Angeles, CA-based company is developing lead candidate ENV 105, which it obtained from its acquisition of Enviro Therapeutics in…
Read More…
KAPA IPO News – Micro-cap cancer biotech Kairos Pharma prices IPO at $4
